Lupin Ltd. has granted Salix Pharmaceuticals, Ltd. exclusive worldwide rights (except for India) to use Lupin technology for all rifaximin products for human use. This agreement expands the companies’ collaboration dating back to September 2009. Under the expanded agreement Lupin will supply Salix with rifaximin API and certain finished rifaximin products.
Lupin will receive a $10 million up-front payment as well as potential U.S. regulatory milestones for products covered by Lupin patents or jointly held patents. Lupin is also eligible to receive royalties on sales. Additionally, Salix will pay Lupin minimum quarterly payments for product development and other activities.